Top in cardiology: GLP-1 receptor agonist roundup; CV heat deaths expected to spike
Click Here to Manage Email Alerts
GLP-1 receptor agonists appear to be an effective way of cutting down on obesity. But there are important adverse events — and ways to avoid them — that patients should be made aware of, according to experts.
Authors of a new Pharmacology Consult column reviewed the major GLP-1 agonists — breaking down their FDA approval statuses, their performance in trials so far and what we know about how they should be prescribed, as well as the promising future for this new class of weight loss drug.
It was the top story in cardiology last week.
Another top story covered a study projecting that based on current climate policies, CV deaths involving extreme heat will sharply rise before 2065 in the United States. Older adults — a growing portion of the population — were projected to see an increase in deaths 3.5 times greater than other age groups, and Black adults are expected to have 4.6 times as many deaths compared with white adults.
Read these and more top stories in cardiology below:
Pharmacology Consult: GLP-1 receptor agonists for weight loss management
Obesity is one of the most common chronic preventable comorbidities affecting adults and children in the United States. Read more.
Heart-related deaths will continue to rise with increased extreme heat, model suggests
CV deaths associated with extreme heat are projected to increase by 162% in the U.S. between now and 2065 when factoring in current climate policies, with the greatest burden on Black and older adults, data show. Read more.
Lack of awareness, treatment of high cholesterol more common among Black, Hispanic adults
Among U.S. adults with elevated LDL, being unaware and untreated was more common among Black and Hispanic adults and those with lower income or without health insurance, data from the National Health and Nutrition Examination Survey show. Read more.
Q&A: Patient trust required before AI-aided remote interventions can be implemented
Much has been written about the potential of artificial intelligence-aided remote interventions to help cardiologists improve patient care, but potential drawbacks and practical issues all must be considered. Read more.
Build trust, offer options when navigating statin intolerance for patients
Statin therapy is a first-line recommendation for all adults with established atherosclerotic vascular disease or at high ASCVD risk, yet studies and anecdotal reports show many patients cannot — or will not — take statins as prescribed. Read more.